Consolidated Planning Corp Has $5.81 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Consolidated Planning Corp boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,163 shares of the company’s stock after purchasing an additional 431 shares during the quarter. Novo Nordisk A/S comprises 1.1% of Consolidated Planning Corp’s holdings, making the stock its 25th biggest position. Consolidated Planning Corp’s holdings in Novo Nordisk A/S were worth $5,810,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after buying an additional 11,727,507 shares during the last quarter. FMR LLC raised its stake in Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after acquiring an additional 6,654,614 shares during the period. Morgan Stanley raised its stake in Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 91.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $718,995,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. UBS Group began coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Finally, BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $1.06 on Friday, hitting $126.85. 3,312,457 shares of the company traded hands, compared to its average volume of 3,307,405. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average price is $126.86 and its 200-day moving average price is $111.98. The company has a market capitalization of $569.24 billion, a price-to-earnings ratio of 46.90, a P/E/G ratio of 2.10 and a beta of 0.41. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.